Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF- κB signal pathway.

CONCLUSION: PLD1 inhibition can remarkably exert antitumor effects with bortezomib on MM, which is a novel potentially targeting therapeutic agent, especially for drug-resistant MM patients. PMID: 33191863 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research